The heparin-releasable proteins are a group of proteins that are targeted to the endothelial surface by attachment to glycosaminoglycans and may have functions specific to the endothelium-blood interface. In this study, heparin-affinity chromatography of human postheparin plasma was used as a method to identify and study novel heparin-releasable proteins. Six proteins seen on sodium dodecyl sulfatepolyacrylamide gel electrophoresis gels have increased levels in plasma after intravenous heparin. The six proteins are platelet factor 4, midkine, pleiotrophin, and several novel proteins. Midkine and pleiotrophin are related cytokines that are developmentally regulated, neurotrophic, and mitogenic. Additional studies show that levels of midkine and pleiotrophin peak at 10 to 30 minutes after injection of heparin. Heparin-releasable midkine and pleiotrophin do not originate from blood cells or the kidney. Heparinreleasable midkine may originate from endothelial cells. Soft agar culture of an adenocarcinoma cell line (SW-13) demonstrates growth-stimulating activity similar to that described for pleiotrophin in the heparin-agarose eluate of postheparin plasma but not in the heparin-agarose eluate of preheparin plasma. It is concluded there are more heparin-releasable proteins than previously identified, including midkine and pleiotrophin, and that heparin-affinity chromatography of postheparin plasma is a useful technique for identifying novel heparin-releasable proteins. 
I n 1943, Hahn 1 discovered that intravenous heparin cleared alimentary lipemia in dogs. The lipidclearing activity was later identified as lipoprotein lipase. Since then, a number of other proteins have been discovered, usually incidentally, to increase in the plasma after intravenous heparin administration. The known heparin-releasable proteins are lipoprotein lipase, 1 hepatic triglyceride lipase, 2 platelet factor 4, 3 tissue factor pathway inhibitor, 4 extracellular superoxide dismutase, 5 diamine oxidase (histaminase), 6 and tumor necrosis factor-binding protein-1. 7 Tissue-type plasminogen activator may also be heparin releasable after its secretion from endothelial cells. 8 The heparinreleasable proteins are diverse in structure, function, and origin; however, with the exception of tumor necrosis factor-binding protein-1, they share the ability to bind heparin-like glycosaminoglycans on the surface of endothelial cells. 913 Intravenous heparin presumably competes for glycosaminoglycan binding sites and releases these proteins into the flowing blood.
The physiological significance of the heparin-releasable property of these proteins is not clear. One possibility is that the heparin-releasable proteins are specif-ically targeted to the endothelial surface by attachment to glycosaminoglycans and that the heparin-releasable proteins have functions specific to the endotheliumblood interface. There is evidence that the known heparin-releasable proteins contribute to vascular homeostasis: the lipases, by providing fatty acids for metabolic and structural needs 9 ; tissue factor pathway inhibitor, by regulating coagulation and protecting vessel patency 14 ; extracellular superoxide dismutase, by protecting the endothelium from oxidative stress"; diamine oxidase (histaminase), by degrading the biologically active and potentially dangerous amines, histamine and putrescine 15 ; platelet factor 4, by regulating inflammatory responses and angiogenesis and opposing the actions of heparin 16 ; and tumor necrosis factor-binding protein-1, by regulating the actions of tumor necrosis factor. 7 A useful technique for isolating heparin-releasable proteins is heparin-affinity chromatography of postheparin plasma (PHP). Five of the seven known heparinreleasable proteins have been isolated from human PHP by heparin-affinity chromatography. 517 - 19 The two exceptions are diamine oxidase, which binds heparin with low affinity, and tumor necrosis factor-binding protein-1, which does not bind heparin at physiological ionic strength. 7 Heparin-affinity chromatography of tissue factor pathway inhibitor is a rapid and powerful separation procedure, providing a > 1000-fold purification from plasma in one step.
fied. To our knowledge, no one has looked for novel heparin-releasable proteins. Second, if there are novel heparin-releasable proteins, they may play physiologically significant roles in vascular homeostasis. Third, heparinaffinity chromatography of PHP is a useful method for identifying novel heparin-releasable proteins. Testing these hypotheses has shown that at least two of them are correct: that there are more heparin-releasable proteins than previously identified and that heparin-affinity chromatography of PHP is a useful technique for identifying novel heparin-releasable proteins.
Methods

Materials
Heparin-agarose type II was from Sigma Chemical Co (St Louis, Mo). One-milliliter HiTrap heparin columns were from Pharmacia LKB (Piscataway, NJ). Immobilon-P (polyvinylidene diflouride [PVDF]) membranes were from Millipore Corp (Bedford, Mass). Porcine intestinal heparin for intravenous injection was from Elkins-Sinn, Inc (Cherry Hill, NJ). Prestained molecular-weight standards were from Bio-Rad (Richmond, Calif). Antibodies used for immunoblots were from the following sources: plasminogen, a 2 -macroglobulin, immunoglobulin M, and albumin from Sigma; apolipoprotein B from Boehringer-Mannheim Biochemicals (Mannheim, FRG); antithrombin III and coagulation factor V from Dakopatts A/S (Glostrup, Denmark); lipoprotein lipase from Chemicon International (Temecula, Calif); coagulation factor VIII from Synbiotics Corp (San Diego, Calif); /3 2 -glycoprotein-l from Diagnostica Stago (Asnieres, France); von Willebrand factor from Atlantic Antibodies (Stillwater, Minn); fibrinogen from Dr Russell Doolittle (University of California at San Diego); tissue factor pathway inhibitor as described 20 ; and coagulation factors IX and X from Dr L.V.M. Rao (University of California at San Diego). All other chemicals were from Sigma or Fisher.
Heparin-Agarose Chromatography of Preheparin Plasma and PHP: Initial Experiment
One hundred twenty milliliters of blood was drawn by venipuncture into syringes containing EDTA (final concentration, 5 mmol/L), aprotinin (200 KIU/mL), diisopropyl fluorophosphate (5 mmol/L), leupeptin (1 mmol/ L), and heparin (10 U/mL). Heparin (7500 U) was injected into the same vein, and 6 minutes later 120 mL of blood was drawn into a similar mixture of EDTA, inhibitors, and heparin. The plasma samples were separated by centrifugation and simultaneously loaded onto separate 10-mL columns of heparin-agarose at 20 mL/h. The columns were washed with 500 mL of 0.14 mol/L NaCl in HEPES-sodium azide buffer (HS; 0.02 mol/L jY-2-hydroxyethylpiperazine-./v"-2-ethanesulfonic acid and 5 mmol/L Na 3 N) and then with 100 mL of 0.3 mol/L NaCl/HS and eluted with 1.75 mol/L NaCl/HS. All fractions with an absorbance >.O25 (l-cm light path) at 280 nm were pooled. One tenth of the total volume of each eluate was used (after 15% trichloroacetic acid [TCA] precipitation as described below) for each lane of the sodium dodecyl sulfate-polyacrylamide gel.
Heparin-Agarose Chromatography of PHP for Amino Acid Sequencing
Heparin (7500 U) was injected intravenously, and 6 minutes later 300 mL of blood was drawn into syringes containing EDTA (final concentration, 5 mmol/L), aprotinin (200 KIU/mL), leupeptin (1 mmol/L), and heparin (10 U/mL). The plasma was separated by centrifugation at 3000g for 20 minutes and frozen at -70°C until use. Seven healthy adult males volunteered for this part of the study, and their plasma samples were pooled. The pooled, frozen plasma (=1 L in volume) was thawed at 37°C and loaded onto a 50-mL column of heparin-agarose at 50 mL/h. The column was washed with 50 column volumes of HS and 10 column volumes of 0.25 mol/L NaCl/HS and eluted with a 1-L linear gradient of saline/HS (from 0.25 to 1.75 mol/L NaCl in HS). Fractions (15 mL) were collected and stored at 4°C until use.
Informed Consent
This study was approved by the Committee on Investigations Involving Human Subjects at the University of California, San Diego. All subjects in the study gave written informed consent.
Functional Assay for Diamine Oxidase (Histaminase)
The functional assay for diamine oxidase was performed according to Tryding's modification 21 of the method of Okuyama and Kobayashi.
Heparin-Agarose Chromatography of Plasmas for Time Course of Midkine and Pleiotrophin Release and From Patients With Renal Failure
Doses and timing of heparin injections were as described in the text. Ten milliliters of blood was drawn into a syringe containing EDTA (5 mmol/L), and the plasma was separated by centrifugation. Two milliliters of the plasma was diluted to 5 mL in the wash buffer and loaded onto the Pharmacia fast protein liquid chromatography system with a 1-mL HiTrap heparin column at 1 mL/min. The column had been equilibrated and was washed with 50 column volumes of 0.2 mol/L NaCl/0.2% Tween-20/ HS/5 mmol/L EDTA and eluted with a 50-mL linear gradient of saline/HS/EDTA (from 0.2 to 1.75 mol/L NaCl in HS/5 mmol/L EDTA). Twenty 2.5-mL fractions were collected and stored at 4°C until use. Fractions 11 and 12, which contained all of the visible midkine and pleiotrophin, were pooled for electrophoresis.
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Column fractions were precipitated with 15% TCA for 45 minutes in an ice-water bath. After centrifugation, the pellets were washed with ice-cold acetone three times and allowed to air dry. Pellets were then resuspended in 50 fiL of SDS-PAGE sample buffer containing 5% /3-mercaptoethanol and 10 (iL of 1.0 mol/L tris(hydroxymethyl)aminomethane-HCl, pH 8.0, and boiled for 3 minutes. Electrophoresis was performed according to Laemmli. 22 Gels were either stained with silver by using the Bio-Rad silver stain kit or transferred to PVDF membranes using the method of Matsudaira.
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Amino Acid Sequencing
Protein bands transferred to PVDF were sequenced with an Applied Biosystems model 470A sequencer equipped with a BLOTT cartridge and employing the O3CBLT program supplied by the manufacturer. Phenyl-thiohydantoin amino acids were analyzed with an Applied Biosystems model 120 high-performance liquid chromatograph, and data reduction was accomplished with a Perkin-Elmer 7500 computer equipped with CHROM 3 software.
Immunoblots
Immunoblotting was performed according to Towbin et al 24 by using secondary antibodies linked to alkaline phosphatase. Primary cultures of human endothelial and smooth muscle cells and culture media were obtained from Clonetics, Inc (San Diego, Calif).
Protein Database Searches
The amino acid sequences obtained were compared with sequences in the NBRF PIR, release 37, database on a Macintosh Ilsi computer using MACVECTOR version 4.1 software (IBI, New Haven, Conn).
Growth Factor Assays
Soft agar culture was performed according to the method of Wellstein et al. 25 Briefly, SW-13 cells (an adrenal adenocarcinoma cell line obtained from the American Type Culture Collection) were grown in monolayer culture, then transferred at 60 000 cells/well into 35-mm wells of six-well tissue-culture plates (Costar), and grown in soft agar with growth medium (improved modified Eagle's medium [IMEM] plus 10% fetal calf serum) plus the samples to be tested. Cells were grown in growth medium alone (negative control), growth medium plus recombinant human basic fibroblast growth factor (rhbFGF; also known as heparinbinding growth factor-2, or HBGF-2) at 50 ng/mL, growth medium plus heparin-agarose eluate from preheparin plasma (NHP), and growth medium plus heparin-agarose eluate from PHP. Three weeks after plating, the number of large foci (>60 /um in diameter) in 15 low-power (xlO) fields were counted. NHP and PHP prepared from two individuals were each assayed in triplicate, and the data were pooled.
Heparin-agarose eluates were prepared starting with 60 mL of EDTA (5 mmol/L) and heparin (10 U/mL) containing NHP and PHP from the same donor. The 0.3 to 1.75 mol/L NaCl eluates were each concentrated with a Centricon 10 (Millipore), washed extensively with sterile phosphate-buffered saline, and sterilized by filtration. Final volumes of both heparin-agarose eluates were 1 mL, and 100 /xL of each was added to the cultured cells for each assay.
Mitogenic assays for MC3T3 cells were performed as described. 26 Briefly, MC3T3 cells were grown to confluence on 48-well tissue-culture plates (Falcon). Heparinagarose eluates from NHP and PHP, as well as bFGF (50 ng/mL), were added to wells along with [
Results
Initial Experiment Identifying Novel Heparin-Releasable Proteins
To verify the presence of novel heparin-releasable proteins, 120 mL of blood (65 mL of plasma) was drawn from a single donor before and 6 minutes after intravenous injection of 7500 U of heparin. The 6-minute time point was chosen because postheparin levels of the tissue factor pathway inhibitor peak at 6 to 8 minutes after injection of heparin. 20 After separation of the plasma samples by centrifugation, they were loaded onto separate but identical heparin-agarose columns, washed extensively with 0.3 mol/L NaCl/HS, and eluted isocratically with 1.75 mol/L NaCl/HS. The heparinagarose eluates of NHP and PHP were run side by side on a 15% SDS-PAGE gel and stained with silver (Fig 1) . The majority of bands represent proteins that appear to be present in equal amounts in both NHP and PHP. A number of these proteins were identified by immunoblotting (not shown) and were found to be antithrombin III (the dominant band at 60 kDa); von Willebrand factor; coagulation factors V, VIII, IX, and X; fibrinogen; plasminogen; /3 2 -glycoprotein-l; a r macroglobulin; albumin; and immunoglobulin M.
By visual examination (Fig 1) , PHP contains at least six bands, at approximately 8,15,17,32, 33, and 34 kDa, that are either not present or present in much lower amounts in NHP. These bands were preliminarily defined as heparin-releasable proteins and have been seen in the PHP but not NHP of 12 healthy control subjects.
Amino Acid Sequencing of Heparin-Releasable Proteins
To identify the heparin-releasable proteins by amino acid sequencing, PHP was obtained from seven healthy adult volunteers, pooled, and loaded onto a heparinagarose column. After extensive washing of the column, it was eluted with a linear gradient of NaCl (from 0.25 to 1.75 mol/L) in HS. Eluted fractions were initially evaluated by silver staining (Fig 2) and immunoblotting (not shown). The elution locations of some known heparinreleasable proteins were determined by functional assay (diamine oxidase), immunoblotting (lipoprotein lipase and tissue factor pathway inhibitor), and amino acid sequenc-
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. ing (platelet factor 4). Tissue factor pathway inhibitor eluted at 0.7 mol/L NaCI (fractions 28 and 31 of Fig 2) ; lipoprotein lipase eluted in two peaks, one at 0.65 mol/L NaCI (fraction 28) and a second at 1.2 mol/L NaCI (fraction 46); diamine oxidase (histaminase) was present in the flowthrough and the 0.25 mol/L NaCI wash; and platelet factor 4 eluted at 1.4 mol/L NaCI (fraction 56). The elution patterns of the novel heparin-releasable proteins are shown in Fig 2. In addition, two new proteins were seen: a 35-kDa protein eluted at 0.8 mol/L NaCI (fraction 34) and a 12-kDa protein eluted at 0.9 mol/L NaCI (fraction 37). The 35-kDa protein has been identified in the PHP but not NHP of four of four volunteers. The 12-kDa protein has been identified in the PHP of only one of four volunteers. The fractions containing the heparin-releasable proteins were pooled, concentrated by TCA precipitation, run on SDS-PAGE, transferred to a PVDF membrane, and sequenced. The obtained amino-terminal, amino acid sequences are shown in the Table. Comparison of the obtained amino acid sequences to those in the NBRF PIR protein database, release 37, confirms that the sequence of the 8-kDa band is that of human platelet factor 4. 16 The sequence of the 15-kDa heparin-releasable protein corresponds to the predicted amino-terminal, amino acid sequence of the retinoic acid-inducible cytokine, midkine. 27 The sequence of the 17-kDa heparin-releasable protein corresponds to the known amino-terminal, amino acid sequence of pleiotrophin, 28 
Time Course of Midkine and Pleiotrophin Release After Heparin Injection
The time course of increase of plasma pleiotrophin and midkine after heparin injection is shown in Fig 3: both appear to peak at =10 to 30 minutes after intravenous injection of 7500 U of heparin. Midkine and pleiotrophin bands were not seen in substantial amounts in serum or in whole blood incubated with 10 U/mL heparin, which demonstrates that heparin-releasable midkine and pleiotrophin do not originate from blood cells.
Heparin-Releasable Midkine and Pleiotrophin in Patients With End-stage Renal Failure
Three patients with end-stage renal failure who were on long-term hemodialysis were studied for the presence of midkine and pleiotrophin in their PHP (Fig 4) . While patients 1 and 2 appear to have somewhat diminished amounts of postheparin midkine relative to pleiotrophin, patient 3, who is anephric after the surgical removal of both kidneys, has heparin-releasable 
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Human pleiotrophin GKKEKPEKKVKKSDXGE GKKEKPEKKVKKSDCGE 32 kDa
The published amino-terminal sequences of human platelet factor 4, midkine, and pleiotrophin are aligned for comparison.
midkine and pleiotrophin. This demonstrates that the kidney is not the main origin of synthesis of heparinreleasable midkine or pleiotrophin.
Endothelial Cell Production of Midkine
Human umbilical vein endothelial cells were cultured, and the conditioned medium was examined by immunoblot for the presence of pleiotrophin and midkine protein. With this procedure, cultured human umbilical vein endothelial cells synthesized midkine but not pleiotrophin (Fig 5) . Human aortic smooth muscle cells were also studied and found not to synthesize either midkine or pleiotrophin (not shown).
Growth Factor Activity of PHP
The biological activities of heparin-agarose eluates from NHP and PHP were determined by their abilities to induce anchorage-independent growth of SW-13 cells, a human adenocarcinoma cell line (Fig 6A) . SW-13 cells were grown in soft agar in the presence of growth medium (IMEM plus 10% fetal calf serum) alone, growth medium plus bFGF (also known as heparin-binding growth factor-2, or HBGF-2) at 50 ng/mL, growth medium plus heparin-agarose eluate from preheparin plasma (NHP or normal human plasma), and growth medium plus a heparin-agarose eluate from PHP. With these assay conditions, PHP was equal in ability to bFGF in supporting the growth of large foci (>60 /Am) of SW-13 cells. NHP was only slightly better than the control medium in promoting growth of SW-13 cells.
To confirm that the activity in the PHP that induced foci formation of SW-13 cells in soft agar was not due to bFGF, these same fractions were tested for mitogenic activity in MC3T3 cells (Fig 6B) . This cell line was chosen because it is known to produce pleiotrophin 29 and presumably would not respond to pleiotrophin stimulation. Indeed, these cells responded to bFGF but not to PHP, NHP, or control medium.
Discussion
Our results show that there are more heparin-releasable proteins than have been previously described and that heparin-affinity chromatography of PHP is a useful method for identifying novel heparin-releasable proteins. These experiments did not address the potential physiological significance of the newly found heparinreleasable proteins. Future experiments will test possible intravascular functions for midkine, pleiotrophin, and the novel heparin-releasable proteins.
It appears likely that the 15-and 17-kDa heparinreleasable proteins are midkine and pleiotrophin on the basis of their molecular weights, heparin binding abilities, and amino-terminal, amino acid sequences. In addition, the heparin-agarose eluate from PHP has growth-stimulating activity for SW-13 cells similar to that described for pleiotrophin. 25 The mitogenic activity cannot be attributed to bFGF, as the heparin-agarose eluate from PHP is not mitogenic for MC3T3 cells, which are responsive to bFGF. It remains possible that the mitogenic activity in PHP is due to a heparinbinding growth factor other than midkine or pleiotrophin. This possibility can be tested as soon as neutralizing antibodies to midkine and pleiotrophin are available.
Midkine and pleiotrophin are recently described cytokine growth factors. Midkine was first cloned in 1988 by Kadomatsu et al 30 while searching for genes that were preferentially transcribed during the retinoic acidinduced differentiation of an embryonal carcinoma cell line. Midkine is developmentally regulated, 31 mitogenic, 32 neurotrophic, 32 and highly conserved across spe- cies. 27 Until now, functional studies of midkine have used recombinant midkine protein produced by bacteria. 32 Ours is the first description of the natural midkine protein. This work also clearly defines the cleavage site between the signal peptide and the secreted midkine protein. The amino-terminal sequence of midkine was predicted to be K-K-K-D-K on the basis of the cDNA sequence, 27 but our data indicate that the true amino terminal sequence is V-A-K-K-K-D-K.
The pleiotrophin protein was purified in 1989 by Milner et al 26 28 This work is the first description of either midkine or pleiotrophin in the intravascular space. The receptors for these two cyto- The sites of synthesis of heparin-releasable midkine and pleiotrophin are not known. A study using in situ hybridization in mouse tissues found significant amounts of midkine only in the kidneys in the adults. 31 Our study demonstrates that one patient without both kidneys still possesses heparin-releasable midkine and pleiotrophin. Cultured umbilical vein endothelial cells synthesize midkine, so the endothelium may be the source of heparin-releasable midkine. Clearly, heparinreleasable midkine and pleiotrophin do not originate from blood cells.
The functions of the 32-, 33-, 34-, and 35-kDa heparin-releasable proteins are not known. The 32-, 33-, and 34-kDa proteins may be related to each other, as they are close in molecular weight and "travel" together during heparin-afnnity chromatography. The 12-kDa protein shown in Fig 2 has not been confirmed to be heparin releasable. To date, it has been identified in the PHP of only one volunteer, a healthy 21-year-old woman taking oral contraceptives. It is hoped that learning the primary sequences of the novel heparinreleasable proteins by cDNA cloning will help to identify their functions.
It is interesting to compare the heparin-releasable proteins with heparin-binding proteins that are not heparin releasable, such as antithrombin HI, factor IX, and von Willebrand factor. First, the heparin-releasable proteins are all trace proteins: the concentration of lipoprotein lipase in PHP is 2 nmol/L, 37 of platelet factor 4 is 30 nmol/L, 19 and of tissue factor pathway inhibitor is 2.5 to 20 nmol/L. 20 The non-heparin-releasable, heparin-binding proteins mentioned above are more abundant: the concentration of antithrombin III is 2.6 ^mol/L, 38 of factor IX is 70 nmol/L, 39 and of von Willebrand factor is 38 nmol/L. 40 Second, the majority of heparin-releasable protein molecules do not circulate. Conversely, the majority of antithrombin III, factor IX, and von Willebrand factor molecules circulate in the blood; whether a minority of molecules reside on the surface of the endothelium cannot be determined by the relatively insensitive methods used in this study. Perhaps differences in binding affinities to glycosaminoglycans or in specificities of binding sites determine how any given protein partitions between the endothelial surface and the circulation.
There are strengths and weaknesses of heparin-affinity chromatography of PHP as a technique for identifying novel heparin-releasable proteins. The strengths of this technique are simplicity, speed, and degree of purification. The heparin-releasable proteins identified in this study required less than a 1-minute exposure to heparin-agarose for complete binding. Rechromatography of the depleted plasma does not remove additional heparin-releasable proteins, which suggests that they completely bind heparin-agarose in the first pass. While the heparin-releasable proteins bind heparin-agarose quickly and completely, < 1 % of the total plasma proteins are eluted from heparin-agarose under the conditions used in this study.
There are at least two weaknesses to heparin-afnnity chromatography of PHP as a technique for identifying novel heparin-releasable proteins. First, this technique may identify only a fraction of the total heparin-releasable proteins. Only one of the seven previously described heparin-releasable proteins was present at high enough concentration to be visualized with this technique and silver staining. In addition, two of the seven previously described heparin-releasable proteins do not bind heparin-agarose in PHP. There may be other heparin-releasable proteins that do not bind heparinagarose in PHP, bind with lower affinity, or are present at concentrations too low for detection by SDS-PAGE and silver staining. There may also be proteins attached to other endothelial glycosaminoglycans, such as dermatan sulfate or chondroitin sulfate, that are not released from the endothelial surface by heparin.
The second weakness of this technique is that we assume that the heparin-releasable proteins are bound to vascular endothelial glycosaminoglycans in vivo, but there are other possible explanations. Heparin may stimulate secretion of some heparin-releasable proteins from intracellular locations. 10 Also, heparin is a highly negatively charged molecule that could potentially interfere with the ionic interaction of some heparinreleasable proteins and oppositely charged molecules on the vascular surface. Also, heparin could potentially release or activate proteases or other enzymes that in turn cause the release of other proteins from the vascular surface. In support of our assumption that the heparin-releasable proteins are, in general, bound to vascular glycosaminoglycans are the following: First, lipoprotein lipase 41 and tissue factor pathway inhibitor 42 are seen with immunostaining to line the endothelial surface. Second, at least five of the seven previously identified heparin-releasable proteins bind endothelial surface glycosaminoglycans in vitro.
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In conclusion, our results demonstrate that there are more heparin-releasable proteins than previously identified, including the cytokines midkine and pleiotrophin, and that heparin-affinity chromatography of PHP is a useful technique for identifying novel heparin-releasable proteins. The identification and characterization of heparin-releasable proteins is of potential value in understanding homeostasis at the endothelium-blood interface and the pharmacology of the commonly used anticoagulant drug heparin.
